The use of corticosteroids in severe sepsis and acute respiratory distress syndrome

Annals of Medicine

Volumn 34, Issue 7-8, 2002, Pages 582-589

  Chadda, Karim ^a   Annane, Djillali ^a  

^a RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Adrenal cortex hormones; Adrenal gland hypofunction; Animals; Cardiovascular system; Clinical trials; Inflammation; Respiratory distress syndrome, adult; Sepsis; Survival analysis

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CORTICOSTEROID ANTAGONIST; CORTICOSTEROID DERIVATIVE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; LIPOCORTIN 1; METHYLPREDNISOLONE; MIFEPRISTONE; PLACEBO; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESISTANCE; DRUG SAFETY; HOMEOSTASIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; LOW DRUG DOSE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SEPTIC SHOCK; VAGUS NERVE;

EID: 0036949072     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/078538902321117805     Document Type: Review

References (72)

1. Waterhouse R. Case of suprarenal apoplexy. Lancet 1911; 1: 577.
2. Friderichsen C. Nebennierenapoplexie bei kleinen Kindern. Jb Kinderheilk 1918; 87: 109.
3. Perla D, Marmorston J. Suprarenal cortical hormone and salt in the treatment of pneumonia and other severe infections. Endocrinology 1940; 27: 367-74.
4. Hahn EO, Houser HB, Rammelkamp CH, Denny FW, Wannamaker LW. Effect of cortisone on acute streptococcal infections and post-streptococcal complications. J Clin Invest 1950; 30: 274-81.
5. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984; 311: 1137-43.
6. Lucas CE, Ledgerwood AM. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg 1984; 119: 537-41.
7. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-8.
8. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317: 659-65.
9. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, et al. High dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987; 317: 1565-70.
10. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988; 138: 62-8.
11. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991; 337: 582-3.
12. Annane D, Sébille V, Troché G, Raphaël JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin JAMA 2000; 283: 1038-45.
13. Molijn GJ, Spek JJ, van Uffelen JC, de Jong FH, Brinkmann AO, Bruining HA, et al. Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab 1995; 80: 1799-803.
14. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, et al. Effect of prolonged methylprenisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998; 280: 159-65.
15. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645-50.
16. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27: 723-32.
17. Lenczowski MJ, Schmidt ED, Van Dam AM, Gaykema RP, Tilders FJ. Individual variation in hypothalamus-pituitary-adrenal responsiveness of rats to endotoxin and interleukin-1 beta. Ann N Y Acad Sci 1998; 856: 139-47.
18. McCann SM, Karanth S, Kamat A, Les Dees W, Lyson K, Gimeno M, et al. Induction by cytokines of the pattern of pituitary hormone secretion in infection. Neuroimmunomodulation 1994; 1: 2-13.
19. Wong ML, Rettori V, Shekhlee A, Bongiorno PB, Canteros G, McCann SM, et al. Inducible nitric oxide synthase gene expression in the brain during systemic inflammation. Nat Med 1996; 2: 581-4.
20. Gonzalez-Hernandez JA, Bornstein SR, Ehrhart-Bornstein M, Späth-Schwalbe E, Jirikowski G, Scherbaum WA. Interleukin-6 messenger ribonucleic acid expression in human adrenal gland in vivo: new clue to a paracrine or autocrine regulation of adrenal function. J Clin Endocrinol Metab 1994; 79: 1492-7.
21. Gonzalez-Hernandez JA, Ehrhart-Bornstein M, Späthschwalbe E, Scherbaum WA, Bornstein SR. Human adrenal cells express tumor necrosis factor-alpha messenger ribonucleic acid - evidence for paracrine control of adrenal function. J Clin Endocrinol Metab 1996; 81: 807-13.
22. Päth G, Bornstein SR, Späthschwalbe E, Scherbaum WA. Direct effects of interleukin-6 on human adrenal cells. Endocr Res 1996; 22: 867-73.
23. Darling G, Goldstein DS, Stull R, Gorschboth CM, Norton JA. Tumor necrosis factor: immune endocrine interaction. Surgery 1989; 106: 1155-60.
24. Gaykema RP, Dijkstra I, Tilders FJ. Subdiaphragmatic vagotomy suppresses endotoxin-induced activation of hypothalamic corticotropin-releasing hormone neurons and ACTH secretion. Endocrinology 1995; 136: 4717-20.
25. Ballard PL, Baxter JD, Higgins SJ, Rousseau GC, Tomkins GM. General presence of glucocorticoid receptors in mammalian tissues. Endocrinology 1974; 94: 998-1002.
26. Beato M. Gene regulation by steroid hormones. Cell 1989; 56: 335-44.
27. Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol 1987; 139: 4129-34.
28. Ray A, Prefontaine KE. Physical Association and Functional Antagonism Between the p65 Subunit of Transcription Factor NF-kappa B and the Glucocorticoid Receptor. Proc Natl Acad Sci USA 1994; 91: 752-6.
29. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin Jr AS. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-6.
30. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 270: 286-90.
31. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (Il)-10 inhibits nuclear factor kappa B (NF-kappa B) activation in human monocytes: Il-10 and Il-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995; 270: 9558-63.
32. Hofmann TG, Hehner SP, Bacher S, Droge W, Schmitz ML. Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress nuclear factor-kappa-B dependent transcription. FFBS Lett 1998; 441: 441-6.
33. Chrousos GP. The stress response and immune function: clinical implications. The 1999 Novera H. Spector Lecture. Ann N Y Acad Sci 2000; 917: 38-67.
34. Tobian L. Interrelationship of electrolytes, juxtaglomerular cells and hypertension. Physiol Rev 1960; 40: 280-312.
35. Grunfeld JP, Eloy L. Glucocorticoids modulate vascular reactivity in the rat. Hypertension 1987; 10: 608-18.
36. McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Archs Derm 1962; 86: 608-10.
37. Yard AC, Kadowitz PJ. Studies on the mechanists of hydrocortisone potentiation of vasoconstrictor responses to epinephrine in the anesthetized animal. Eur J Pharmacol 1972; 20: 1-9.
38. Kelly JJ, Mangos G, Williamson PM, Whitworth JA. Cortisol and hypertension. Clin Exp Pharmacol Physiol Suppl 1998; 25: S51-6.
39. Thiemermann C, Vane JR. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 1990; 182: 591-5.
40. Paya D, Gray GA, Fleming I, Stoclet JC. Effect of dexamethasone on the onset and persistence of vascular hyporeactivity induced by E. coli lipopolysaccharide in rats. Circ Shock 1993; 41: 103-12.
41. May ME, Vaughan ED, Carey RM. Adrenocortical insufficiency-clinical aspects. In: Vaughan ED Jr, Carey RM, eds. Adrenal disorders. New York: Thieme Medical; 1989: 171-89.
42. Tordjman K, Jaffe A, Grazas N, Apter C, Stern N. The role of the low dose (1 μg) adrebnocorticotropin test in the evaluation of patients with pituitary disease. J Clin Endocrinol Metab 1995; 80: 1301-5.
43. Koo DJ, Jackman D, Chaudry IH, Wang P. Adrenal insufficiency during the late stage of polymicrobial sepsis. Crit Care Med 2001; 29: 618-22.
44. Tayek JA, Atienza VJ. Pituitary adrenal axis function in systemic inflammatory response syndrome. Endocrine 1995; 3: 1055-9.
45. Annane D, Bellissant E, Sebille V, Lesieur O, Mathieu B, Raphael JC, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998; 46: 589-97.
46. Beishuizen A, Thijs LG, Vermes I. Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med 2001; 27: 1584-91.
47. Rook G, Baker R, Walker B, Honour J, Jessop D, Hernadez-Pando R, et al. Local regulation of glucocorticoid activity in sites of inflammation: insights from the study of tuberculosis. Ann N Y Acad Sci 2000; 917: 913-22.
48. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB. Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol 1991; 146: 3523-7.
49. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. Combination of IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993; 151: 3460-6.
50. Molijn GJ, Kuper JW, van Uffelen CJ, de Jong FH, Brinkmann AO, Bruining HA, et al. Temperature-induced down-regulation of the glucocorticoid receptor in peripheral blood mononuclear leucocyte in patients with sepsis or septic shock. Clin Endocrinol 1995; 43: 197-203.
51. Barber AE, Coyle SM, Fischer E, Smith C, van der Poll T, Shires GT et al. Influence of hypercortisolemia on soluble tumor necrosis factor receptor II and interleukin-1 receptor antagonist responses to endotoxin in human beings. Surgery 1995; 118: 406-10.
52. van der Poll T, Barber AE, Coyle SM, Lowry SF. Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia - a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3604-6.
53. Briegel J, Kellermann W, Forst H, Haller M, Bittl M, Hoffmann GE, et al. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The phospholipase A2 study group. Clin Investig 1994; 72: 782-7.
54. Key D. Effects of hydrocortisone on the immune response in patients with septic shock - results from a double-blind cross-over study. J Anästh Intens 1999; 1: S195-6.
55. Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998; 158: 1432-41.
56. van Leeuwen HJ, van der Bruggen T, van Asbeck S, Boereboom FTJ. Effects of corticosteroids on nuclear factor - kB activation and hemodynamics in late septic shock. Crit Care Med 2001; 29: 1074-7.
57. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome and in response: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002; 165: 983-91.
58. Szabo C, Thiemermann C, Wu CC, Perretti M, Vane JR. Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo. Proc Natl Acad Sci USA 1994; 91: 271-5.
59. Bhagat K, Collier J, Valance P. Local venous responses to endotoxin in humans. Circulation 1996; 94: 490-7.
60. Barber AE, Coyle SM, Marano MA, Fischer E, Calvano SE, Fong Y, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993; 150: 1999-2006.
61. Bellissant E, Annane D. Effect of hydrocortisone on phenylephrine - mean arterial pressure dose - response relationship in septic shock. Clin Pharmacol Ther 2000; 68: 293-303.
62. Chawla K, Kupfer Y, Tessler S. Hydrocortisone reverses refractory septic shock. Crit Care Med 1999; 27: A33.
63. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, et al. Effect of a 7-Day Treatment with Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients with Septic Shock. JAMA (in press).
64. McKee JI, Finlay WEI. Cortisol replacement in severely stressed patients. Lancet 1983; 1: 284.
65. Ashbaugh DG, Maier RV. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome. Diagnosis and treatment. Arch Surg 1985; 120: 530-5.
66. Hooper RG, Kearl RA. Established ARDS treated with sustained course of adrenocortical steroids. Chest 1990; 97: 138-43.
67. Meduri GU, Belenchia JM, Estes RJ, Wunderink RG, El Torky M, Leeper KV Jr. Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. Chest 1991; 100: 943-52.
68. Meduri GU, Chinn AJ, Leeper KV Jr, Wunderink RG, Tolley E, Winer-Muram HT, et al. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS. Pattern of response and predictors of outcome. Chest 1994; 105: 1516-27.
69. Biffl WL, Moore FA, Moore EE, Haenel JB, Mc Intyre RC Jr, Burch JM. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome? Am J Surg 1995; 170: 591-6.
70. Hooper RG, Kearl RA. Established adult respiratory distress syndrome successfully treated with corticosteroids. South Med J 1996; 89: 359-64.
71. Keel JBP, Hauser M, Stocker R, Baumann PC, Speich R. Established acute respiratory distress syndrome: benefit of corticosteroid rescue therapy. Respiration 1998; 65: 258-64.
72. Yildiz O, Doganey M, Aygen B, Güven M, Kelestimur F, Tutus A. Physiological dose steroid therapy in sepsis. Crit Care 2002; 6: 251-8.